--- title: "Targeted Therapy Is Not a One-and-Done Solution: Watch for These Serious Cancer-Related Emergencies" url: "https://www.yyhmedical.com/en/news/targeted-therapy-dic-emergency-warning" type: Article inLanguage: en-US category: Expert Insights datePublished: 2026-05-29 --- # Targeted Therapy Is Not a One-and-Done Solution: Watch for These Serious Cancer-Related Emergencies > Dr. Shuang LI of Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, uses a case of EGFR-mutant lung cancer to explain how to recognize dangerous complications such as disseminated intravascular coagulation (DIC) and how they are managed. Summary: Dr. Shuang LI of Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, discusses a real clinical case involving a patient with lung cancer harboring an EGFR exon 21 L858R mutation who developed disseminated intravascular coagulation (DIC) after resistance to targeted therapy and rapid disease progression. The article explains how cancer-associated DIC develops, why clotting and bleeding can occur at the same time, and which warning signs patients and families should watch for. It also emphasizes an important point: targeted therapy itself is not necessarily the cause of DIC. Rather, rapidly progressive cancer can trigger severe coagulation abnormalities. Close monitoring, early recognition of emergencies, and individualized treatment that combines control of the underlying cancer, correction of coagulation abnormalities, and supportive care are all essential parts of whole-course cancer management. As precision oncology continues to advance, targeted therapies have helped many patients with driver mutation-positive lung cancer live longer and maintain a better quality of life. But even after a period of stable disease, some patients may experience sudden progression or develop serious, potentially life-threatening complications. Using a real case from clinical rounds, this article highlights one dangerous but easily overlooked cancer-related emergency. The goal is to help patients and families recognize warning signs earlier and seek medical care promptly. **01 A Real Clinical Case: A Life-Threatening Complication After Disease Progression** During a recent ward round at Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, Dr. Shuang LI reviewed the case of a 54-year-old woman with lung cancer and an EGFR exon 21 L858R sensitizing mutation. This type of mutation is generally sensitive to EGFR-targeted therapy. The patient had previously received standard third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, which controlled her disease for a period of time. During treatment, however, resistance to targeted therapy developed and the cancer progressed rapidly. She subsequently developed a critical complication: disseminated intravascular coagulation (DIC). It is important to understand that patients with rapidly progressive cancer can develop DIC because of the cancer itself, regardless of whether targeted therapy is being used. Rapid tumor growth, tumor necrosis, and vascular invasion can release large amounts of procoagulant substances into the bloodstream and activate the body's coagulation system. In this case, the rapid progression after targeted therapy resistance accelerated an already dangerous process. **02 What Is Cancer-Associated DIC?** Disseminated intravascular coagulation (DIC) is a severe disorder of blood clotting that can occur in advanced cancer. It is a medical emergency that can cause a patient's condition to deteriorate quickly and may become life-threatening. **In simple terms, the process may involve three overlapping problems:** (1) Tiny blood clots form throughout small and larger blood vessels, blocking circulation and reducing blood and oxygen supply to organs. (2) Large amounts of platelets and clotting factors are consumed. (3) As these clotting components are depleted, serious bleeding can develop, including bruising or bleeding of the skin and mucous membranes, internal bleeding, or intracranial hemorrhage. **Typical Clinical Features** (1) Clotting and bleeding may occur at the same time, without a clear boundary between the two phases. (2) The condition can progress very quickly and requires urgent medical intervention. (3) Platelet counts may fall markedly, and coagulation tests may become significantly abnormal. **When this patient was admitted, she had already developed:** (1) Shortness of breath and inability to lie flat, requiring supplemental oxygen; (2) Widespread small thrombi in the bronchial arteries, as well as thrombosis in the superior and inferior vena cava; (3) Pleural and pericardial effusions; (4) Enlarged lymph nodes in multiple areas, including the axillae, supraclavicular regions, and lower neck. **What Should Patients and Families Take Away from This?** (1) Resistance to targeted therapy can eventually develop, and the cancer may then progress rapidly. (2) Rapid cancer progression can trigger medical emergencies such as coagulation disorders and organ failure. (3) Unexplained chest tightness, shortness of breath, inability to lie flat, extensive bruising, or unusual bleeding should be assessed urgently by a medical team. **03 Individualized, Multidisciplinary Treatment Can Create a Window for Recovery** For critically ill patients with cancer-associated DIC, treatment needs to be rapid, individualized, and multidimensional. (1) Treat the underlying cancer: adjust anticancer therapy according to the mechanism of resistance and work to regain disease control. (2) Manage the emergency: correct coagulation abnormalities according to the patient's current DIC pattern and clinical status. (3) Provide supportive care: replace blood components or clotting factors when appropriate, use anticoagulation selectively when indicated, and protect organ function. After intensive, individualized treatment and close monitoring, the patient's cancer was brought under better control. Her pleural and pericardial effusions decreased substantially, enlarged lymph nodes regressed, her breathing improved, and she was again able to lie flat. Her overall clinical condition improved significantly. This case shows that a cancer-related emergency does not always mean there are no options left. Early recognition, rapid intervention, and appropriate treatment may still create an opportunity to stabilize the patient and improve the situation. *DIC can develop as cancer progresses. If you notice large unexplained bruises, persistent gum or nose bleeding, continued oozing from an injection or puncture site, or these symptoms together with chest tightness, severe shortness of breath, inability to lie flat, dizziness, profound weakness, or low blood pressure, seek emergency medical care immediately. Do not wait for the symptoms to resolve on their own. Early recognition and treatment are critical for safety.* *Targeted therapy has transformed lung cancer care and made longer-term disease control possible for many patients. But effective treatment also requires whole-course management, close follow-up, and prompt recognition of emergencies.* *Cancer treatment is an ongoing process. Changes in symptoms, laboratory results, or sudden new discomfort can all be important signals from the body. Understanding these warning signs, attending regular follow-up, communicating promptly with the care team, and acting quickly when needed can help protect both treatment safety and effectiveness.* --- Original (HTML):https://www.yyhmedical.com/en/news/targeted-therapy-dic-emergency-warning This is a clean Markdown mirror for large language models; the original page is authoritative.